For the year ending 2025-12-31, ELVN has $476,168K in assets. $16,568K in debts. $98,896K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 98,896 | |||
| Marketable securities | 363,725 | |||
| Restricted cash | 0 | |||
| Prepaid expenses and other current assets | 12,257 | |||
| Total current assets | 474,878 | |||
| Property and equipment, net | 34 | |||
| Operating lease right-of-use assets | 383 | |||
| Deferred offering costs | 217 | |||
| Other long-term assets | 656 | |||
| Total assets | 476,168 | |||
| Accounts payable | 2,159 | |||
| Accrued expenses and other current liabilities | 14,409 | |||
| Total current liabilities | 16,568 | |||
| Total liabilities | 16,568 | |||
| Common stock, par value 0.001 authorized shares - 100,000,000 issued and outstanding shares - 59,440,045 and 48,936,459 at december 31, 2025 and 2024, respectively | 59 | |||
| Additional paid-in capital | 806,373 | |||
| Accumulated other comprehensive income | 334 | |||
| Accumulated deficit | -347,166 | |||
| Total stockholders' equity | 459,600 | |||
| Total liabilities and stockholders' equity | 476,168 | |||
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)